文献速递前列腺癌肾癌与肾肿瘤膀胱癌与上尿路尿路上皮癌

美国泌尿肿瘤远程医疗使用趋势与患者特征

Telehealth in Urologic Oncology: Temporal Trends and Patient Characteristics in the United States.
PubMed 文献 · Urology · 2026-08-27

基于Merative MarketScan商业保险索赔数据库,分析2010至2023年膀胱、肾、前列腺和睾丸癌门诊索赔中远程医疗的使用趋势、患者预测因素及下游费用。远程医疗仅占泌尿肿瘤索赔的0.25%,2020年达1.93%后降至2023年1.06%;远程医疗新患者就诊的患者自付费用较低,而保险公司支付费用相当。

要点

  • 远程医疗在泌尿肿瘤索赔中占比极低,2020年峰值1.93%,2023年降至1.06%。
  • 男性、西部居民、非PPO保险者更可能使用远程医疗;非城市居民和高合并症负担者使用较少。
  • 远程医疗新患者就诊的患者自付费用较低,保险公司支付费用与面对面就诊相当。

核心结论

  • 远程医疗在泌尿肿瘤中的使用因癌症类型、地点和保险而异,可能降低患者费用。

研究设计与样本

  • 基于Merative MarketScan商业保险索赔数据库的回顾性队列研究,提取2010至2023年膀胱、肾、前列腺和睾丸癌门诊索赔,分析大流行前(2010-2019)和大流行时期(2020-2022)两个时间队列。

主要发现

  • 共85,237次远程医疗就诊,占泌尿肿瘤索赔的0.25%;2020年使用率达1.93%,2023年降至1.06%。
  • 男性(OR 1.4;P <.001)、西部居民(OR 1.6;P <.001)和非PPO保险(OR 1.2;P <.001)更可能使用远程医疗;非城市居民(OR 0.68;P <.001)和高合并症负担(OR 0.92;P <.001)使用较少。
  • 前列腺癌和肾癌远程医疗使用率最高,膀胱癌最低。
  • 远程医疗启动的新患者肿瘤就诊在大流行前(SR 0.49;P = .011)和大流行时期(SR 0.82;P = .0001)队列中患者自付费用较低;保险公司支付费用相当。

临床怎么用

  • 远程医疗可作为泌尿肿瘤新患者就诊的可选方式,尤其可能降低患者自付费用,但需考虑患者地域、保险类型和合并症负担等因素。

局限性

  • 研究基于商业保险索赔数据库,可能不涵盖无保险或其他保险类型患者,且远程医疗使用率低可能限制普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To better characterize population-level data on utilization trends, patient-level predictors, and downstream costs of telehealth use across GU malignancies using a national commercial insurance claims database. METHODS: We extracted bladder, kidney, prostate, and testis cancer outpatient claims from the Merative MarketScan database. Telehealth claims were flagged from 2010 to 2023, and multivariable modeling was used to identify patient-level factors. Weighted generalized linear models were used to compare twelve-month insurer-paid and out-of-pocket spending after telehealth or in-person new patient visits. Two time-range cohorts were analyzed: pre-pandemic (2010-2019) and pandemic-era (2020-2022). RESULTS: There were 85,237 telehealth visits, which represented 0.25% of GU oncology claims. Telehealth use reached 1.93% in 2020 and fell to 1.06% by 2023. Men (OR 1.4; P <.001), patients in the West (OR 1.6; P <.001), and those with non-PPO insurance (OR 1.2; P <.001) were more likely to use telehealth; non-urban patients (OR 0.68; P <.001) and those with higher comorbidity burden (OR 0.92; P <.001) were less likely. Prostate and kidney cancer had the highest telehealth rates; bladder cancer had the lowest. New patient oncology visits initiated via telehealth had lower patient out-of-pocket (OOP) spending in the pre-pandemic (SR 0.49; P = .011) and pandemic-era (SR 0.82; P = .0001) cohorts. Insurer-paid spending was comparable. CONCLUSION: Telehealth use in urologic oncology varies by cancer type, location, and insurance. It may lower costs for patients, which warrants further investigation and policy investment.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Weitzner AS, Kodavatikanti A, Alvim L, et al. Telehealth in Urologic Oncology: Temporal Trends and Patient Characteristics in the United States. Urology. 2026. PMID: 42660326. doi:10.1016/j.urology.2026.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。